|
Cambridge Biotechnology, the developer of obesity treatments with 29 staff, has been acquired by Biovitrum of Sweden for undisclosed terms. 23-Mar-2005 Cambridge Biotechnology has received £6m of venture capital to fund the development of new treatments for pain and obesity. 25-Jul-2002
|